Ignite Creation Date:
2025-12-24 @ 1:05 PM
Ignite Modification Date:
2026-01-03 @ 7:23 PM
Study NCT ID:
NCT02083861
Status:
COMPLETED
Last Update Posted:
2018-05-07
First Post:
2014-03-07
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Wearable LITUS Device for Osteoarthritis of the Knee: a Randomized Double-Blind Placebo-Controlled Trial
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D020370', 'term': 'Osteoarthritis, Knee'}, {'id': 'D010003', 'term': 'Osteoarthritis'}, {'id': 'D001168', 'term': 'Arthritis'}, {'id': 'D003240', 'term': 'Connective Tissue Diseases'}, {'id': 'D010146', 'term': 'Pain'}, {'id': 'D008224', 'term': 'Lymphoma, Follicular'}], 'ancestors': [{'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D012216', 'term': 'Rheumatic Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D008228', 'term': 'Lymphoma, Non-Hodgkin'}, {'id': 'D008223', 'term': 'Lymphoma'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'rodoc@cnymail.com', 'phone': '(607) 844-9979', 'title': 'Dr. Ralph Ortiz', 'organization': 'Pain Management Associates'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}, 'limitationsAndCaveats': {'description': 'Small number of patients enrolled in range of motion and strength study may have limited statistical analysis. Future studies should include larger sample sizes.'}}, 'adverseEventsModule': {'timeFrame': '8 weeks (study duration)', 'description': 'No adverse events (serious or non-serious) were observed. Patients were supplied with daily diaries where adverse reactions could be self reported. Additionally, follow-up appointments assessed for adverse reactions during weeks 1, 3 (baseline) and week 5, 7, 8 (intervention period).', 'eventGroups': [{'id': 'EG000', 'title': 'Active Ultrasound Device', 'description': 'Patients (n=55) receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.\n\nSam Ultrasonic Diathermy Device: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.', 'otherNumAtRisk': 55, 'deathsNumAtRisk': 55, 'otherNumAffected': 0, 'seriousNumAtRisk': 55, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Placebo Ultrasound Device', 'description': 'Patients (n=35) wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.\n\nSam Ultrasonic Diathermy Device: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.', 'otherNumAtRisk': 35, 'deathsNumAtRisk': 35, 'otherNumAffected': 0, 'seriousNumAtRisk': 35, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Pain on the Numeric Rating Scale (NRS) Change From Baseline to Study Conclusion', 'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'OG000'}, {'value': '33', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Active Ultrasound Device', 'description': 'Patients (n=55) receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.\n\nSam Ultrasonic Diathermy Device: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.'}, {'id': 'OG001', 'title': 'Placebo Ultrasound Device', 'description': 'Patients (n=35) wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.\n\nSam Ultrasonic Diathermy Device: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.96', 'groupId': 'OG000', 'lowerLimit': '-2.92', 'upperLimit': '-1.00'}, {'value': '-0.85', 'groupId': 'OG001', 'lowerLimit': '-1.96', 'upperLimit': '0.26'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 6', 'description': 'The numeric rating scale (NRS) was used to assess change in pain from baseline to study conclusion. NRS range from 0-10 with 0 being no pain and 10 the worst pain possible.', 'unitOfMeasure': 'units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Patients that completed the entire study were included in analysis.'}, {'type': 'SECONDARY', 'title': 'Quality of Life (WOMAC) Change From Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'OG000'}, {'value': '33', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Active Ultrasound Device', 'description': 'Patients (n=55) receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.\n\nSam Ultrasonic Diathermy Device: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.'}, {'id': 'OG001', 'title': 'Placebo Ultrasound Device', 'description': 'Patients (n=35) wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.\n\nSam Ultrasonic Diathermy Device: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.'}], 'classes': [{'title': 'WOMAC Pain Score Change', 'categories': [{'measurements': [{'value': '-107.3', 'groupId': 'OG000', 'lowerLimit': '-147.6', 'upperLimit': '-66.8'}, {'value': '-60.8', 'groupId': 'OG001', 'lowerLimit': '-100.3', 'upperLimit': '-21.2'}]}]}, {'title': 'WOMAC Stiffness Score Change', 'categories': [{'measurements': [{'value': '-45.0', 'groupId': 'OG000', 'lowerLimit': '-61.1', 'upperLimit': '-28.9'}, {'value': '-17.1', 'groupId': 'OG001', 'lowerLimit': '-36.0', 'upperLimit': '-1.9'}]}]}, {'title': 'WOMAC Function Score Change', 'categories': [{'measurements': [{'value': '-352.3', 'groupId': 'OG000', 'lowerLimit': '-480.7', 'upperLimit': '-224.0'}, {'value': '-220.1', 'groupId': 'OG001', 'lowerLimit': '-334.3', 'upperLimit': '-105.9'}]}]}, {'title': 'WOMAC Total Score Change', 'categories': [{'measurements': [{'value': '-504.6', 'groupId': 'OG000', 'lowerLimit': '-683.4', 'upperLimit': '-325.7'}, {'value': '-311.2', 'groupId': 'OG001', 'lowerLimit': '-473.4', 'upperLimit': '-148.9'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 6', 'description': 'WOMAC questionnaire will be utilized (Western Ontario and McMaster Universities Arthritis Index). WOMAC was divided into 3 categories: pain, stiffness, function and total score. The pain category consists of five scores from 0-10, 0 is no pain 10 is worst pain possible for a range of 0 - 50 points. The stiffness category consists of two scores from 0-10, 0 is no stiffness 10 is worst stiffness possible for a range of 0 - 20 points. The function score consists of 17 scores from 0-10, 0 is normal function and 10 is severely limited function, for a range of 0 - 170 points. Categories were multiplied by 10 for analysis. Total score is the sum of pain, stiffness, and function scores (range of 0 - 2400).', 'unitOfMeasure': 'units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Patients that completed the entire study were included in analysis.'}, {'type': 'SECONDARY', 'title': 'Range of Motion Change From Baseline in Treated Knee', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Active Ultrasound Device', 'description': 'Patients (n=9) receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.\n\nSam Ultrasonic Diathermy Device: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.'}, {'id': 'OG001', 'title': 'Placebo Ultrasound Device', 'description': 'Patients (n=8) wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.\n\nSam Ultrasonic Diathermy Device: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.'}], 'classes': [{'title': 'Flexion Change', 'categories': [{'measurements': [{'value': '-6.38', 'groupId': 'OG000', 'lowerLimit': '-40.5', 'upperLimit': '27.8'}, {'value': '-2.22', 'groupId': 'OG001', 'lowerLimit': '-29.1', 'upperLimit': '24.6'}]}]}, {'title': 'Extension Change', 'categories': [{'measurements': [{'value': '-17.75', 'groupId': 'OG000', 'lowerLimit': '-52.5', 'upperLimit': '17.0'}, {'value': '-5.56', 'groupId': 'OG001', 'lowerLimit': '-33.2', 'upperLimit': '22.1'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 6', 'description': 'JTech equipment was used to evaluate range of motion range of motion using an inclinometer (www.jtechmedical.com) in flexion and extension of the treated knee. 0 degrees is fully extended and 150 degrees is normal flexion. Positive flexion change indicates improvement in flexion. Negative extension indicates improvement in extension.', 'unitOfMeasure': 'Degrees', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': '17 patient subset was assessed for range of motion pilot data.'}, {'type': 'SECONDARY', 'title': 'Muscle Strength Change From Baseline in Treated Knee', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Active Ultrasound Device', 'description': 'Patients (n=9) receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.\n\nSam Ultrasonic Diathermy Device: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.'}, {'id': 'OG001', 'title': 'Placebo Ultrasound Device', 'description': 'Patients (n=8) wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.\n\nSam Ultrasonic Diathermy Device: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.'}], 'classes': [{'title': 'Flexion', 'categories': [{'measurements': [{'value': '1.34', 'groupId': 'OG000', 'lowerLimit': '-2.22', 'upperLimit': '4.89'}, {'value': '1.01', 'groupId': 'OG001', 'lowerLimit': '-4.06', 'upperLimit': '6.08'}]}]}, {'title': 'Rotation', 'categories': [{'measurements': [{'value': '3.21', 'groupId': 'OG000', 'lowerLimit': '0.23', 'upperLimit': '6.06'}, {'value': '0.68', 'groupId': 'OG001', 'lowerLimit': '-3.89', 'upperLimit': '5.25'}]}]}, {'title': 'Extension', 'categories': [{'measurements': [{'value': '1.91', 'groupId': 'OG000', 'lowerLimit': '-3.03', 'upperLimit': '6.85'}, {'value': '1.60', 'groupId': 'OG001', 'lowerLimit': '-2.74', 'upperLimit': '5.94'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline to 6 Weeks', 'description': 'Muscle strength in flexion, extension, and rotation were measured using JTECH muscle testing equipment.', 'unitOfMeasure': 'Newtons', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': '17 patient subset was assessed for muscle strength pilot data.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Active Ultrasound Device', 'description': 'Patients (n=55) receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.\n\nSam Ultrasonic Diathermy Device: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.'}, {'id': 'FG001', 'title': 'Placebo Ultrasound Device', 'description': 'Patients (n=35) wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.\n\nSam Ultrasonic Diathermy Device: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '57'}, {'groupId': 'FG001', 'numSubjects': '36'}]}, {'type': 'Treated', 'achievements': [{'groupId': 'FG000', 'numSubjects': '55'}, {'groupId': 'FG001', 'numSubjects': '35'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '51'}, {'groupId': 'FG001', 'numSubjects': '33'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '3'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '55', 'groupId': 'BG000'}, {'value': '35', 'groupId': 'BG001'}, {'value': '90', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Active Ultrasound Device', 'description': 'Patients (n=55) receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.\n\nSam Ultrasonic Diathermy Device: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.'}, {'id': 'BG001', 'title': 'Placebo Ultrasound Device', 'description': 'Patients (n=35) wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.\n\nSam Ultrasonic Diathermy Device: Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'BG000'}, {'value': '33', 'groupId': 'BG001'}, {'value': '84', 'groupId': 'BG002'}]}], 'categories': [{'measurements': [{'value': '53.6', 'groupId': 'BG000', 'lowerLimit': '35', 'upperLimit': '80'}, {'value': '51.1', 'groupId': 'BG001', 'lowerLimit': '35', 'upperLimit': '72'}, {'value': '52.6', 'groupId': 'BG002', 'lowerLimit': '35', 'upperLimit': '80'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'FULL_RANGE', 'populationDescription': 'Only patients that completed study included.'}, {'title': 'Sex: Female, Male', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'BG000'}, {'value': '33', 'groupId': 'BG001'}, {'value': '84', 'groupId': 'BG002'}]}], 'categories': [{'title': 'Female', 'measurements': [{'value': '28', 'groupId': 'BG000'}, {'value': '17', 'groupId': 'BG001'}, {'value': '45', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '23', 'groupId': 'BG000'}, {'value': '16', 'groupId': 'BG001'}, {'value': '39', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'populationDescription': 'Only patients that completed study included.'}, {'title': 'BMI', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'BG000'}, {'value': '33', 'groupId': 'BG001'}, {'value': '84', 'groupId': 'BG002'}]}], 'categories': [{'measurements': [{'value': '34.9', 'spread': '8.9', 'groupId': 'BG000'}, {'value': '34.5', 'spread': '8.3', 'groupId': 'BG001'}, {'value': '34.7', 'spread': '8.6', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'kg/m2', 'dispersionType': 'STANDARD_DEVIATION', 'populationDescription': 'Only patients that completed study included.'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 93}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2014-03'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-04', 'completionDateStruct': {'date': '2014-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-04-02', 'studyFirstSubmitDate': '2014-03-07', 'resultsFirstSubmitDate': '2017-02-27', 'studyFirstSubmitQcDate': '2014-03-10', 'lastUpdatePostDateStruct': {'date': '2018-05-07', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2018-04-02', 'studyFirstPostDateStruct': {'date': '2014-03-11', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2018-05-07', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2014-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Pain on the Numeric Rating Scale (NRS) Change From Baseline to Study Conclusion', 'timeFrame': 'Baseline, Week 6', 'description': 'The numeric rating scale (NRS) was used to assess change in pain from baseline to study conclusion. NRS range from 0-10 with 0 being no pain and 10 the worst pain possible.'}], 'secondaryOutcomes': [{'measure': 'Quality of Life (WOMAC) Change From Baseline', 'timeFrame': 'Baseline, Week 6', 'description': 'WOMAC questionnaire will be utilized (Western Ontario and McMaster Universities Arthritis Index). WOMAC was divided into 3 categories: pain, stiffness, function and total score. The pain category consists of five scores from 0-10, 0 is no pain 10 is worst pain possible for a range of 0 - 50 points. The stiffness category consists of two scores from 0-10, 0 is no stiffness 10 is worst stiffness possible for a range of 0 - 20 points. The function score consists of 17 scores from 0-10, 0 is normal function and 10 is severely limited function, for a range of 0 - 170 points. Categories were multiplied by 10 for analysis. Total score is the sum of pain, stiffness, and function scores (range of 0 - 2400).'}, {'measure': 'Range of Motion Change From Baseline in Treated Knee', 'timeFrame': 'Baseline, Week 6', 'description': 'JTech equipment was used to evaluate range of motion range of motion using an inclinometer (www.jtechmedical.com) in flexion and extension of the treated knee. 0 degrees is fully extended and 150 degrees is normal flexion. Positive flexion change indicates improvement in flexion. Negative extension indicates improvement in extension.'}, {'measure': 'Muscle Strength Change From Baseline in Treated Knee', 'timeFrame': 'Baseline to 6 Weeks', 'description': 'Muscle strength in flexion, extension, and rotation were measured using JTECH muscle testing equipment.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['osteoarthritis', 'arthritis', 'musculoskeletal', 'connective tissue disease', 'ultrasound', 'pain', 'mobility', 'heat', 'strength', 'ZetrOZ', 'LITUS', 'Sam', 'grade 1', 'grade 2'], 'conditions': ['Knee Osteoarthritis']}, 'referencesModule': {'references': [{'pmid': '30326947', 'type': 'DERIVED', 'citation': 'Draper DO, Klyve D, Ortiz R, Best TM. Effect of low-intensity long-duration ultrasound on the symptomatic relief of knee osteoarthritis: a randomized, placebo-controlled double-blind study. J Orthop Surg Res. 2018 Oct 16;13(1):257. doi: 10.1186/s13018-018-0965-0.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to measure the effectiveness of a wearable therapeutic ultrasound device in patients with stage I and stage II knee osteoarthritis. The ability of the device to reduce pain, increase mobility, increase range of motion and muscle strength of the affected leg, and improve quality of life in patients with knee osteoarthritis will be evaluated.', 'detailedDescription': 'This is an eight week study to clinically evaluate the effect of the low intensity long duration ultrasound (LITUS) device on symptoms of patients suffering from knee osteoarthritis. The device, sam® has been FDA-cleared for use. For the first two weeks of the study, baseline data will be collected as patients report pain scores (NRS) three times per day. During the following 6 weeks, patients will self-apply the wearable LITUS device to their affected knee for 4 hours daily. Each day of the study, pain scores (NRS) will be recorded immediately before application of LITUS device as well as 30 minutes, 2-hours and 4-hours after applying the device. A quality of life assessment (WOMAC), muscle strength and range of motion assessment (JTech) will be performed prior to the patient beginning the protocol and at the conclusion of the protocol.\n\nUp to 93 subjects will be recruited from neighboring communities to the study site. The study is designed to reach a target patient population which includes rural citizens and socioeconomic disadvantaged individuals where non-pharmacotherapies do not exist to manage pain. Subjects will be randomly assigned to active (60%) and placebo groups (40%). The sponsor and investigators are blinded as to which type of device each patient is assigned.\n\nThe study will be monitored by an external monitor and a data safety monitoring board (DSMB).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '35 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Physician-diagnosed mild to moderate knee osteoarthritis (OARSI atlas grades 1-2) based on fixed-flexion x-ray radiological findings for osteophytes and joint space narrowing within the past 12 months\n* Fulfill the American College of Rheumatology clinical and radiological diagnostic criteria for knee OA\n* 35-80 years of age\n* Report a frequent pain score between 3-7 (NRS range: 0-10) during the week preceding enrollment\n* Report that knee pain negatively affects quality of life\n* Willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved ultrasound gel provided to the subject at the initiation of the study\n* Deemed appropriate by their physician or by the study site physician to participate\n\nExclusion Criteria:\n\n* Cannot successfully demonstrate the ability to put on and take off the device\n* Display any condition which, in the judgment of the investigator, would make participation in the study unacceptable, including, but not limited to, the subject's ability to understand and follow instructions.\n* Have severe OA or have little to no cartilage in the knee\n* Have knee replacement, other surgical intervention, or hyaluronidase injection in the affected knee in the past 6 months\n* Are non-ambulatory\n* Participated in a clinical trial for an investigational drug and/or agent within 30 days prior to screening\n* Modify their medications during the course of the study (medications and doses must remain constant throughout the study)\n* Currently taking steroids\n* Have contraindication to radiograph\n* Have a secondary cause of arthritis (metabolic or inflammatory)"}, 'identificationModule': {'nctId': 'NCT02083861', 'briefTitle': 'Wearable LITUS Device for Osteoarthritis of the Knee: a Randomized Double-Blind Placebo-Controlled Trial', 'organization': {'class': 'INDUSTRY', 'fullName': 'ZetrOZ, Inc.'}, 'officialTitle': 'ZetrOZ Wearable Ultrasound Clinical Study', 'orgStudyIdInfo': {'id': 'OA-03'}, 'secondaryIdInfos': [{'id': '1R43MD008597-01', 'link': 'https://reporter.nih.gov/quickSearch/1R43MD008597-01', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Active ultrasound device', 'description': 'Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.', 'interventionNames': ['Device: Sam Ultrasonic Diathermy Device']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo ultrasound device', 'description': 'Patients wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.', 'interventionNames': ['Device: Sam Ultrasonic Diathermy Device']}], 'interventions': [{'name': 'Sam Ultrasonic Diathermy Device', 'type': 'DEVICE', 'otherNames': ['ZetrOZ ultrasound device', 'wearable ultrasound device', 'long duration ultrasound', 'LITUS device', 'long duration low intensity device'], 'description': 'Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.', 'armGroupLabels': ['Active ultrasound device', 'Placebo ultrasound device']}]}, 'contactsLocationsModule': {'locations': [{'zip': '13053', 'city': 'Dryden', 'state': 'New York', 'country': 'United States', 'facility': 'Medical Pain Consultants', 'geoPoint': {'lat': 42.49091, 'lon': -76.29716}}], 'overallOfficials': [{'name': 'Ralph Ortiz, D.O., MPH', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Medical Pain Consultants'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'ZetrOZ, Inc.', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'National Institutes of Health (NIH)', 'class': 'NIH'}, {'name': 'National Institute on Minority Health and Health Disparities (NIMHD)', 'class': 'NIH'}], 'responsibleParty': {'type': 'SPONSOR'}}}}